Romana Höftberger1, Theodor W May2, Christian G Bien3, Corinna I Bien4, Müjgan Dogan Onugoren5, Desiree De Simoni1,6, Verena Eigler7, Carl-Albrecht Haensch8, Martin Holtkamp9, Fatme S Ismail10, Martin Kurthen11, Nico Melzer12, Kristina Mayer13, Felix von Podewils14, Helmut Rauschka15, Andrea O Rossetti16, Wolf-Rüdiger Schäbitz17, Olga Simova18, Karsten Witt19. 1. Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria. 2. Society of Epilepsy Research, Bielefeld, Germany. 3. Epilepsy Center Bethel, Krankenhaus Mara, Maraweg 17-21, 33617, Bielefeld, Germany. christian.bien@gmx.de. 4. Laboratory Krone, Bad Salzuflen, Germany. 5. Department of Neurology, Epilepsy Center, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Germany. 6. Department of Neurology, University Hospital St. Poelten, St. Poelten, Austria. 7. Department of Neurology, Städtisches Klinikum Ludwigshafen Am Rhein, Ludwigshafen, Germany. 8. Department of Neurology, Kliniken Maria Hilf Moenchengladbach, Faculty of Health, University of Witten/Herdecke, Moenchengladbach, Germany. 9. Epilepsy-Center Berlin-Brandenburg, Institute for Diagnostics of Epilepsy, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany. 10. Department of Neurology, University Hospital Bochum, Knappschaftskrankenhaus, Bochum, Germany. 11. Swiss Epilepsy Center, Zurich, Switzerland. 12. Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. 13. Department of Neurology, University Hospital of Augsburg, Augsburg, Germany. 14. Department of Neurology, University Medicine Greifswald, Greifswald, Germany. 15. Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost, Donauspital, Vienna, Austria. 16. Department of Clinical Neurosciences, University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. 17. Department of Neurology, EvKB-Bethel, Bielefeld, Germany. 18. Protestant Hospital Alsterdorf, Epilepsy Center Hamburg, Hamburg, Germany. 19. Department of Neurology and Research Centre of Neurosensory Sciences, Carl Von Ossietzky University, Oldenburg, Germany.
Abstract
OBJECTIVE: To determine frequencies, interlaboratory reproducibility, clinical ratings, and prognostic implications of neural antibodies in a routine laboratory setting in patients with suspected neuropsychiatric autoimmune conditions. METHODS: Earliest available samples from 10,919 patients were tested for a broad panel of neural antibodies. Sera that reacted with leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-2 (CASPR2), or the voltage-gated potassium channel (VGKC) complex were retested for LGI1 and CASPR2 antibodies by another laboratory. Physicians in charge of patients with positive antibody results retrospectively reported on clinical, treatment, and outcome parameters. RESULTS: Positive results were obtained for 576 patients (5.3%). Median disease duration was 6 months (interquartile range 0.6-46 months). In most patients, antibodies were detected both in CSF and serum. However, in 16 (28%) patients with N-methyl-D-aspartate receptor (NMDAR) antibodies, this diagnosis could be made only in cerebrospinal fluid (CSF). The two laboratories agreed largely on LGI1 and CASPR2 antibody diagnoses (κ = 0.95). The clinicians (413 responses, 71.7%) rated two-thirds of the antibody-positive patients as autoimmune. Antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), NMDAR (CSF or high serum titer), γ-aminobutyric acid-B receptor (GABABR), and LGI1 had ≥ 90% positive ratings, whereas antibodies against the glycine receptor, VGKC complex, or otherwise unspecified neuropil had ≤ 40% positive ratings. Of the patients with surface antibodies, 64% improved after ≥ 3 months, mostly with ≥ 1 immunotherapy intervention. CONCLUSIONS: This novel approach starting from routine diagnostics in a dedicated laboratory provides reliable and useful results with therapeutic implications. Counseling should consider clinical presentation, demographic features, and antibody titers of the individual patient.
OBJECTIVE: To determine frequencies, interlaboratory reproducibility, clinical ratings, and prognostic implications of neural antibodies in a routine laboratory setting in patients with suspected neuropsychiatric autoimmune conditions. METHODS: Earliest available samples from 10,919 patients were tested for a broad panel of neural antibodies. Sera that reacted with leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-2 (CASPR2), or the voltage-gated potassium channel (VGKC) complex were retested for LGI1 and CASPR2 antibodies by another laboratory. Physicians in charge of patients with positive antibody results retrospectively reported on clinical, treatment, and outcome parameters. RESULTS: Positive results were obtained for 576 patients (5.3%). Median disease duration was 6 months (interquartile range 0.6-46 months). In most patients, antibodies were detected both in CSF and serum. However, in 16 (28%) patients with N-methyl-D-aspartate receptor (NMDAR) antibodies, this diagnosis could be made only in cerebrospinal fluid (CSF). The two laboratories agreed largely on LGI1 and CASPR2 antibody diagnoses (κ = 0.95). The clinicians (413 responses, 71.7%) rated two-thirds of the antibody-positive patients as autoimmune. Antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), NMDAR (CSF or high serum titer), γ-aminobutyric acid-B receptor (GABABR), and LGI1 had ≥ 90% positive ratings, whereas antibodies against the glycine receptor, VGKC complex, or otherwise unspecified neuropil had ≤ 40% positive ratings. Of the patients with surface antibodies, 64% improved after ≥ 3 months, mostly with ≥ 1 immunotherapy intervention. CONCLUSIONS: This novel approach starting from routine diagnostics in a dedicated laboratory provides reliable and useful results with therapeutic implications. Counseling should consider clinical presentation, demographic features, and antibody titers of the individual patient.
Entities:
Keywords:
Autoimmune encephalitis; Immunotherapy; Laboratory test evaluation; Neural autoantibodies; Outcome
Authors: Liane Dahm; Christoph Ott; Johann Steiner; Beata Stepniak; Bianca Teegen; Sandra Saschenbrecker; Christian Hammer; Kathrin Borowski; Martin Begemann; Sandra Lemke; Kristin Rentzsch; Christian Probst; Henrik Martens; Jürgen Wienands; Gianfranco Spalletta; Karin Weissenborn; Winfried Stöcker; Hannelore Ehrenreich Journal: Ann Neurol Date: 2014-06-23 Impact factor: 10.422
Authors: Frank Boesebeck; Oliver Schwarz; Bernhard Dohmen; Ulrike Graef; Thomas Vestring; Corinna Kramme; Christian G Bien Journal: J Neurol Date: 2013-05-17 Impact factor: 4.849
Authors: C G Bien; Z Mirzadjanova; C Baumgartner; M D Onugoren; T Grunwald; M Holtkamp; S Isenmann; P Kermer; N Melzer; M Naumann; M Riepe; W R Schäbitz; T J von Oertzen; F von Podewils; H Rauschka; T W May Journal: Eur J Neurol Date: 2016-10-27 Impact factor: 6.089
Authors: Christian G Bien; Cathrin Rohleder; Juliane K Mueller; Corinna I Bien; Dagmar Koethe; F Markus Leweke Journal: Front Psychiatry Date: 2021-03-26 Impact factor: 4.157
Authors: Franziska S Thaler; Luise Zimmermann; Stefan Kammermeier; Christine Strippel; Marius Ringelstein; Andrea Kraft; Kurt-Wolfram Sühs; Jonathan Wickel; Christian Geis; Robert Markewitz; Christian Urbanek; Claudia Sommer; Kathrin Doppler; Loana Penner; Jan Lewerenz; Rosa Rößling; Carsten Finke; Harald Prüss; Nico Melzer; Klaus-Peter Wandinger; Frank Leypoldt; Tania Kümpfel Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-10-01
Authors: Anna Rada; Robert Birnbacher; Claudio Gobbi; Martin Kurthen; Albert Ludolph; Markus Naumann; Ulrike Neirich; Tim J von Oertzen; Gerhard Ransmayr; Matthias Riepe; Mareike Schimmel; Oliver Schwartz; Rainer Surges; Christian G Bien Journal: J Neurol Date: 2020-10-06 Impact factor: 4.849